Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial. Wu X, Liu J, Wang J, Wang L, et al. Nat Med 2024 May 15. doi: 10.1038/s41591-024-03003.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Wu X, Liu J, Wang J, Wang L, et al. Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial. Nat Med 2024 May 15. doi: 10.1038/s41591-024-03003.
PMID: 38750351